MX2022009399A - Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica. - Google Patents
Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.Info
- Publication number
- MX2022009399A MX2022009399A MX2022009399A MX2022009399A MX2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A MX 2022009399 A MX2022009399 A MX 2022009399A
- Authority
- MX
- Mexico
- Prior art keywords
- life
- roflumilast
- plasma half
- formulation
- improved delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/778,845 US11129818B2 (en) | 2017-06-07 | 2020-01-31 | Topical roflumilast formulation having improved delivery and plasma half life |
| PCT/US2021/015740 WO2021155173A1 (en) | 2020-01-31 | 2021-01-29 | Topical roflumilast formulation having improved delivery and plasma half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009399A true MX2022009399A (es) | 2022-09-19 |
Family
ID=74759470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009399A MX2022009399A (es) | 2020-01-31 | 2021-01-29 | Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4096630A1 (pt) |
| JP (1) | JP2023513092A (pt) |
| KR (1) | KR20220134617A (pt) |
| CN (1) | CN115551478A (pt) |
| AU (1) | AU2021214399A1 (pt) |
| BR (1) | BR112022015104A2 (pt) |
| CA (1) | CA3166300A1 (pt) |
| IL (1) | IL295172A (pt) |
| MX (1) | MX2022009399A (pt) |
| WO (1) | WO2021155173A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024058848A1 (en) * | 2022-09-15 | 2024-03-21 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU687087B2 (en) | 1993-07-02 | 1998-02-19 | Takeda Gmbh | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| CN101491520B (zh) | 2002-05-28 | 2011-03-16 | 尼科梅德有限责任公司 | 局部应用的药物制剂 |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| KR20210044191A (ko) * | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
-
2021
- 2021-01-29 EP EP21708433.4A patent/EP4096630A1/en active Pending
- 2021-01-29 IL IL295172A patent/IL295172A/en unknown
- 2021-01-29 CA CA3166300A patent/CA3166300A1/en active Pending
- 2021-01-29 JP JP2022546613A patent/JP2023513092A/ja active Pending
- 2021-01-29 KR KR1020227029999A patent/KR20220134617A/ko active Search and Examination
- 2021-01-29 CN CN202180017566.3A patent/CN115551478A/zh active Pending
- 2021-01-29 AU AU2021214399A patent/AU2021214399A1/en active Pending
- 2021-01-29 MX MX2022009399A patent/MX2022009399A/es unknown
- 2021-01-29 BR BR112022015104A patent/BR112022015104A2/pt unknown
- 2021-01-29 WO PCT/US2021/015740 patent/WO2021155173A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3166300A1 (en) | 2021-08-05 |
| JP2023513092A (ja) | 2023-03-30 |
| AU2021214399A1 (en) | 2022-08-25 |
| CN115551478A (zh) | 2022-12-30 |
| WO2021155173A1 (en) | 2021-08-05 |
| IL295172A (en) | 2022-09-01 |
| BR112022015104A2 (pt) | 2022-09-27 |
| EP4096630A1 (en) | 2022-12-07 |
| KR20220134617A (ko) | 2022-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
| MX2022013808A (es) | Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad. | |
| BR112013004698A2 (pt) | composições farmacêuticas compreendendo derivados de poh | |
| MX2022009399A (es) | Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica. | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| MX2023014565A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
| MX2024004994A (es) | Métodos para tratar el cáncer de ovário con extracto de cáñamo. | |
| MX2021005240A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| EP4356966A3 (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| WO2023107574A3 (en) | Lipid-based compositions and methods thereof | |
| WO2023137403A3 (en) | Compound comprising raltitrexed or 5-mthf linked to a therapeutic agent, composition, and method of use | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2022005448A (es) | Método de tratamiento de queratodermia palmoplantar. | |
| MX2021009637A (es) | Tratamientos combinados para su uso en el tratamiento del cancer. | |
| MX2024001939A (es) | Administracion retrograda de composicion terapeutica mediante seno o vena coronarios. | |
| MX2023012301A (es) | Metodos para tratar estenosis esofagicas. | |
| MX2022006155A (es) | Terapias anticancerosas con anamicina liposomica orientadas al pulmon. | |
| ZA202203203B (en) | Bicyclic agonists of stimulator of interferon genes sting | |
| JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
| MX2022012353A (es) | Metodos para el inicio de la dosis de los tratamientos con aripiprazol. | |
| EP4364812A3 (en) | Intranasal administration of ketamine to cluster headache patients |